Home Archive
Archive
2025 Volume 46 Issue 9  Published: 2025-09-10
    Topic
  • Xinyi XU , Qian ZHAO , Xiaohui MO , Qiang JU
    doi: 10.13683/j.wph.2025.09.001

    Hidradenitis suppurative(HS) is a chronic, recurrent skin disease of follicular inflammatory, accompanied by multiple comorbidities. At present, the pathogenesis of HS remains unclear, with activation of innate immune system and various inflammatory cytokines. In recent years, biological agents and molecular targeted drugs targeting these targets have shown certain efficacy and application prospects for HS. This article reviewed the clinical research progress of different biologics and molecular targeted drugs in the treatment of HS and HS with comorbidities.

  • Topic
  • Bei GUO , Fei WU , Yan QIANG
    doi: 10.13683/j.wph.2025.09.002

    Tumor vaccine therapy activates and enhances the body's natural immune response against tumor cells by utilizing specific antigens present in the tumor microenvironment. These antigens are specifically expressed by tumor-specific proteins only in tumor cells, are not affected by central immune tolerance, and have both high immunogenicity and tumor specificity, making them ideal targets for treatment and a promising direction for personalized immunotherapy. Although the research and application of immunotherapy in malignant melanoma has a long history and has achieved significant results, there are still considerable limitations. This article reviewed the types and mechanisms of tumor vaccines related to malignant melanoma and analyze the effectiveness and limitations of each type of vaccine.

  • Article
  • Miaoyan FAN , Xinyu WEI , Yingying LU , Junqin MAO , Songpo WANG , Ru'nan QU
    doi: 10.13683/j.wph.2025.09.003
    Objective

    To investigate the mechanism of Huazhuo Chengqi decoction in intervening acute hypertriglyceridemic pancreatitis(AHP) based on network pharmacology and molecular docking.

    Methods

    Components and targets of Huazhuo Chengqi decoction were screened using traditional Chinese medicine systems pharmacology database and analysis platform, traditional Chinese medicine information database, and comparative toxicogenomics database(CTD) database, and the intersected were taken. Cytoscap3.7.2 software was used to construct the network diagram of ''HZCQD-active ingredients-targets'', STRING platform was used to analyze the protein-protein interaction. Metascape platform was performed to conduct enrichment analysis. AutoDock was used to validate the molecular docking.

    Results

    A total of 79 active components in Huazhuo Chengqi decoction were obtained, including quercetin, kaempferol, naringenin, isorhamnetin, and aloe-emodin, ect. Key targets included caspase(CASP)9, CASP3, TP53, Akt1, and nuclear factor(NF)-κB1. These can significantly affect the pathways of lipid regulation and atherosclerosis, nucleotide oligomerization domain-like receptor, mitogen-activated protein kinase, NF-κB and phosphoinositide 3-kinase-Akt signaling pathways. Molecular docking confirmed strong binding between active components and key targets.

    Conclusion

    Huazhuo Chengqi decoction exerts lipid-modulating and anti-inflammatory effects through multi-target and multi-pathway synergy to intervene in AHP, providing a theoretical basis for clinical application.

  • Article
  • Lei LEI , Zhiyi YANG , Tao HUANG , Jin FAN
    doi: 10.13683/j.wph.2025.09.004
    Objective

    To explore the clinical effect of tirofiban combined with ginkgo biloba diterpene lactone in the treatment of acute cerebral infarction(ACI), and its influence on nerve function and hemorheology.

    Methods

    A total of 150 patients with ACI who received treatment in our hospital from June 2021 to June 2023 were selected, and divided into the control group and combined medication group by simple randomization method, with 75 patients in each group. Both groups received conventional treatment and were also given tirofiban, while the combined group received ginkgo biloba diterpene lactone in addition to the control group. Observe and compare The clinical efficacy, the changes in neurological deficits, daily living abilities, serum inflammatory factor levels, coagulation function indicators, hemorheological indicators and the occurrence of adverse reactions in the two groups were observed and compared.

    Results

    The total effective rate of the combined medication group was higher than the control group(94.67% vs. 80.00%, P<0.05). After treatment, the scores of the National Institutes of Health Stroke Scale, serum C-reactive protein, interleukin-6, and tumor necrosis factor alpha levels in both groups decreased compared to before treatment, and the combined medication group was lower than the control group(P<0.05). The scores of activities of daily living in both groups improved compared to before treatment, and the combined medication group was higher than the control group(P<0.05). After treatment, the fibrinogen, D-dimer, whole blood low-shear viscosity, whole blood high-shear viscosity, and plasma viscosity in both groups decreased compared to before treatment, and those in the combined medication group were lower than the control group(P<0.05). The prothrombin time and activated partial thromboplastin time increased compared to before treatment, and those in the combined medication group were higher than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Tirofiban combined with ginkgo biloba diterpene lactone in the treatment of ACI can significantly improve the clinical efficacy, effectively improve the neurological impairment and daily living ability of patients, reduce the level of serum inflammatory factors, optimize the coagulation function and hemorheological indexes, and has high safety.

  • Article
  • Yingying XUE , Jinkun LIU , Weiyi HUANG , Yuhong WANG
    doi: 10.13683/j.wph.2025.09.005
    Objective

    To evaluate the efficacy and safety of Zhangyanming tablets combined with Western medicine in the treatment of primary open angle glaucoma(POAG).

    Methods

    A total of 106 patients with POAG in the ophthalmology outpatient department of our hospital from September 2022 to June 2024 were collected and randomly divided into the control group and the observation group, with 53 cases in each group. The control group was given basic western medical treatment, while the observation group was treated with Zhangyanming tablets in combination with the control group. Both groups were treated continuously for 12 weeks. The best corrected visual acuity(BCVA), intraocular pressure, mean defect degree of visual field, visual field index and average thickness of the retinal nerve fiber layer(RNFL) around the optic disc were compared between the two groups. As well as the linear density and perfusion density of the macula, optic disc and peripapillary vessels, the traditional Chinese medicine(TCM) syndrome score and the total effective rate of treatment were statistically analyzed.

    Results

    A total of 100 patients completed the study, with 50 cases in each of the two groups. After treatment, there were no significant differences in BCVA, intraocular pressure, mean deviation of visual field, and perfusion density of macular, optic disc and peridisc vessels between the two groups(P>0.05). The TCM syndrome score in the observation group were significantly lower than those in the control group(P<0.05), while the visual field index, the average thickness of RNFL, and the linear density of macular, optic disc and peridisc blood vessels in the observation group were significantly higher than those in the control group(P<0.05). The total effective rate of the observation group was higher than that of the control group(82.0% vs. 52.0%, P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    The combination of Zhangyanming tablets and western medicine can significantly improve visual field defects in patients with POAG, increase the average thickness of the RNFL, improve vascular microcirculation in the macula, optic disc and peridisc vessels, effectively alleviate ocular symptoms, and has good safety.

  • Article
  • Chunyan LI , Yuanxin LI , Feiyi ZHAO , Huiru WANG , Wenjing ZHANG
    doi: 10.13683/j.wph.2025.09.006
    Objective

    To explore the short-term and medium-term efficacy and safety of the Shugan Bushen formula in treating perimenopausal insomnia accompanied by depression.

    Methods

    A total of 92 patients with perimenopausal insomnia accompanied by depression who visited the outpatient department of Shanghai traditional Chinese medicine hospital from August 2022 to May 2023 were selected and randomly divided into the experimental group(Shugan Bushen granules) and the placebo group(Shugan Bushen granules placebo) in a 1∶1 ratio, with 46 cases in each group. the treatment course was 6 weeks. The improvements of sleep, mood, and perimenopausal symptoms, changes in hormone levels were compared, and the occurrence of adverse reactions were observed between the two groups.

    Results

    There were significant differences in the scores of Hamilton depression rating scale(HAMD)-17, insomnia severity index, Kupperman menopause index, Pittsburgh sleep quality index, Menopause depression scale and menopausal specific quality of life questionnaire between the two groups at 6 weeks and 8 weeks of treatment(P<0.05). At the 16th week, there was still a significant difference in HAMD-17 in the experimental group(P<0.05). No obvious abnormalities were observed in safety indicators before and after treatment.

    Conclusion

    The Shugan Bushen formula has certain short-term and medium-term clinical efficacy in improve insomnia, depression, and perimenopausal symptoms in patients with insomnia accompanied by depression, but it can not reverse hormonal changes. The formula exhibits a high safety profile.

  • Article
  • Jijie JIANG , Shibin HAN , Mengxu LI
    doi: 10.13683/j.wph.2025.09.007
    Objective

    To explore the effect of dapagliflozin combined with valsartan in the treatment of diabetic nephropathy(DN) and its influence on cystatin(Cys)-C.

    Methods

    A total of 110 patients with DN who visited the endocrinology department of Linquan county people's hospital from June 2022 to January 2025 were selected as the research subjects and randomly divided into the observation group and the control group, with 55 cases in each group. The control group was treated with dapagliflozin, while the observation group was treated with dapagliflozin combined with valsartan. The treatment courses were 8 weeks for both groups. After treatment, the clinical efficacy, Cys-C, urinary albumin excretion rate(UAER), β2-globulin(β2-MG), serum creatinine(Scr), fasting palsma glucose(FPG), 2-hour postprandial blood glucose(2hPG), glycosylated hemoglobin(Hb)A1c, erythrocyte sedimentation rate(ESR), C-reactive protein(CRP), serum amyloid protein(SA)A levels and the occurrence of adverse reactions during the treatment period of the two groups were compared.

    Results

    After treatment, the total effective rate of the observation group was higher than that of the control group(87.27% vs. 70.91%, P<0.05). The levels of Cys-C, UAER, β2-MG, Scr, ESR, CRP, SAA, FPG, 2hPG and HbA1c in both groups were lower than those before treatment(P<0.05), and those in the observation group were lower than those in the control group(P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Dapagliflozin combined with valsartan has a better therapeutic effect on DN. It can improve Cys-C and renal function, and contribute to the reduction of inflammatory factors levels.

  • Article
  • Huiping HU , Wenchun LIU
    doi: 10.13683/j.wph.2025.09.008
    Objective

    To study the effects of levetiracetam combined with perampanel on the discharge index and electroencephalogram(EEG) manifestations of benign childhood epilepsy with centrotemporal spikes(BECT).

    Methods

    A total of 95 children with admitted to the department of pediatric neurorespiratory in our hospital were selected as the research subjects and randomly divided into the control group(n=47) and the study group(n=48). The control group was treated with levetiracetam, while the study group was treated with perampanel in combination on the control group. The clinical effects after treatment, the discharge index during the episode of electroencephalogram, the differences in the α, θ, and δ bands of EEG, and the differences between language intelligence quotient and operational intelligence quotient were compared between the two groups. The occurrence of adverse reactions during the treatment period was also monitored.

    Results

    After treatment, the total effective rate of the control group was lower than that of the study group(78.72% vs. 95.83%, P<0.05). The difference in discharge index of the study group was greater than that of the control group(P<0.05). The improvement rate of the study group was higher than that of the control group(91.67% vs.70.21%, P<0.05). The differences in the α, θ and δ bands of EEG activity in the study group were all higher than those in the control group(P<0.05). The differences in language intelligence quotient scores and operational intelligence quotient scores of the study group were both higher than those of the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Levetiracetam combined with perampanel can effectively improve the discharge index of children with , enhance the improvement effect of EEG, promote the recovery of cognitive function, and has good safety.

  • Article
  • Haixin LAN , Shixian ZHOU , Lanyan SONG , Siming HUANG , Huanqiong LI , Guangxiu HUANG
    doi: 10.13683/j.wph.2025.09.009
    Objective

    To observe the effect of vitamin K on nutritional vitamin D deficiency rickets(VDDR) in children.

    Methods

    A total of 100 children with VDDR admitted to the Department of Pediatrics in our hospital from April 2023 to April 2024 were selected and randomly divided into the control group(n=50, oral vitamin D) and the study group(n=50, oral vitamin D and vitamin K4). Both groups were continuously treated for 2 weeks. The bone mineral density (BMD), bone-specific alkaline phosphatase(B-ALP), and osteocalcin(OC), undercarboxylated OC(ucOC), prostaglandin(PG)E2, tumor necrosis factor(TNF)-α, interleukin(IL)-1β and the occurrence of adverse reactions were compared between the two groups.

    Results

    After treatment, the BMD of the radius and ulna in both groups was higher than that before treatment(P<0.05), and the study group was higher than the control group(P<0.05). After treatment, the levels of B-ALP, OC, ucOC, PGE2, TNF-α and IL-1β in both groups were lower than those before treatment(P<0.05), and the study group were lower than the control group(P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Vitamin K can improve BMD in children with VDDR, regulate the levels of B-ALP, OC, ucOC, PGE2, TNF-α and IL-1β, and does not increase the risk of adverse reactions.

  • Article
  • Li LIU , Rui ZHANG , Xiaowei WANG
    doi: 10.13683/j.wph.2025.09.010
    Objective

    To explore the application effect of Cangfu Daotan decoction in obese polycystic ovary syndrome(PCOS) with phlegm-damp stagnation syndrome and its influence on fat-related factors.

    Methods

    A randomized, double-blind, and superior trial design was adopted. A total of 103 obese patients with PCOS who were treated in our hospital from January 2022 to June 2023 were selected and randomly divided into the study group(n=52) and the control group(n=51). All patients were given conventional treatment, including improving metabolism and regulating endocrine, etc. The study group was additionally treated with Cangfu Daotan decoction. The clinical efficacy, leptin(LEP), adiponectin(APN), follicle stimulating hormone(FSH), and luteinizing hormone(LH), testosterone(T), blood lipid levels, insulin function and the occurrence of complications were compared between the two groups.

    Results

    After treatment, the total clinical effective rate of the study group was higher than that of the control group(88.46% vs. 72.55%), and the difference was significant(P<0.05). The APN levels in both groups were increased compared with those before(P<0.05), and the study group was higher than the control group(P<0.05). The levels of LEP, total cholesterol, triglycerides, low-density lipoprotein cholesterol, FSH, LH, T, homeostasis model assessment of insulin resistance, Vaspin, Apelin and traditional Chinese medicine syndrome score in both groups were decreased compared with those before(P<0.05), and those in the study group were lower than those in the control group(P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Adding Cangfu Daotan decoction to the conventional treatment of obese PCOS patients with phlegm-damp stagnation syndrome can help improve the therapeutic effect, effectively improve the levels of fat-related factors, and bring certain benefits.

  • Article
  • Guanghui LIU , Junfeng SUN
    doi: 10.13683/j.wph.2025.09.011
    Objective

    To explore the efficacy of vonoprazan in patients with gastroesophageal reflux disease(GERD) and its influence on gastric mucosal barrier function.

    Methods

    A total of 120 GERD patients admitted to our hospital from January 2023 to December 2024 were selected and randomly divided into the observation group and the control group, with 60 cases in each group. The control group was treated with rabeprazole, while the observation group was treated with vonoprazan, both for 4 weeks. The clinical efficacy, Los Angeles classification score, GERD-Q, 24-hour pH resistance monitoring results, pepsinogen(PG) Ⅰ/Ⅱ, gastrin(GAS), motilin(MTL), tumor necrosis factor(TNF)-α, interleukin(IL)-6, and high-sensitivity C-reactive protein(hs-CRP), reflux conditions and adverse reactions were compared between the two groups.

    Results

    The total effective rate of the observation group was higher than that of the control group(91.67% vs. 76.67%, P<0.05). The Los Angeles classification and GRED-Q score of the observation group were both lower than those of the control group(P<0.05). The number of times the reflux time was ≥5 min, the longest reflux time, and the pH<4 time in the observation group were all less(shorter) than those in the control group(P<0.05) . The levels of PGⅠ/Ⅱ, GAS and MTL in the observation group were all higher than those in the control group(P<0.05), and TNF-α, IL-6 and hs-CRP were all lower(P<0.05).

    Conclusion

    Vonoprazan has a significant therapeutic effect on GERD and helps repair the gastric mucosal barrier function. Its mechanism might be related to potent acid suppression, anti-inflammation, etc.

  • Article
  • Yuan YU , Dan CAO , Ting GUO , Quan ZHENG
    doi: 10.13683/j.wph.2025.09.012
    Objective

    To explore the therapeutic effects and immune function of Heluo Shugan tablets as an adjuvant treatment in patients with hepatitis B virus decompensated cirrhosis.

    Methods

    A total of 80 patients with hepatitis B virus decompensated cirrhosis admitted to our hospital from January 2022 to June 2024 were selected and divided into the control group and the observation group, with 40 cases in each group. The control group received conventional treatment, while the observation group was treated in combination with Heluo Shugan tablets. Both groups received continuous treatment for 6 months. The clinical efficacy, hepatitis B virus deoxyribonucleic acid(HBV-DNA) load, alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(TBil), hyaluronic acid(HA), laminin(LN), procollagen type Ⅲ peptide(PC-Ⅲ), type Ⅳ collagen(Ⅳ-C), spleen thickness, inner diameter of portal vein, inner diameter of splenic vein, changes of cluster of differentiation antigen(CD)3+, CD4+, CD4+/CD8+, adverse reactions, complications and recompensatory conditions between the two groups were compared.

    Results

    After treatment, the total effective rates of Western medicine treatment(95.00% vs. 62.50%) and traditional Chinese medicine treatment(92.50% vs. 70.00%) in the observation group were both higher than those in the control group, and the differences were significant(P<0.05). Compared with the control group, the HBV-DNA load, ALT, AST, TBil, HA, LN, PC-Ⅲ, Ⅳ-C, spleen thickness, portal vein inner diameter and splenic vein inner diameter in the observation group were all lower, and CD3+, CD4+, CD4+/CD8+ were all higher, with significant differences(P<0.05). There was no statistically significant difference in the incidence of adverse reactions and complications between the two groups(P>0.05). The follow-up was conducted until April 2025. The recompensation rate of the observation group was higher than that of the control group(37.84% vs. 16.67%), and the difference was significant(P<0.05).

    Conclusion

    The use of Heluo Shugan tablets in patients with hepatitis B virus decompensated cirrhosis has received good application feedback and has relatively good safety.

  • Article
  • Tao SHEN , Wei LI , Xiaotian XIE
    doi: 10.13683/j.wph.2025.09.013
    Objective

    To investigate the therapeutic efficacy of doxycycline for macrolide-resistant Mycoplasma pneumoniae pneumonia(MRMP) in Chinese children after the corona virus disease 2019(COVID-19) pandemic.

    Methods

    Clinical data from MRMP studies in Chinese children over the past two years and the key parameters included clinical features(symptoms, signs, laboratory/imaging findings), drug efficacy and safety were collected through medical database searches. A systematic analysis evaluated the effectiveness and safety of doxycycline monotherapy for pediatric MRMP.

    Results

    A total of 200 pediatric MRMP cases were included. The overall effective rate of doxycycline was 88.5%(177/200), with fever reduction observed within 1.39 - 3.96 days after administration. No significant efficacy difference existed between severe Mycoplasma pneumoniae pneumonia group and non-severe Mycoplasma pneumoniae pneumonia group(83.1% vs. 91.1%, P>0.05). Adverse reactions to doxycycline occurred in only 5.5% of cases and were mild doxycycline significantly outperformed intravenous azithromycin in efficacy(92.6% vs. 67.6%, P<0.001), with comparable adverse reaction rates(7.4% vs. 9.5%, P>0.05).

    Conclusion

    Doxycycline has demonstrated significant clinical efficacy and good safety in pediatric MRMP. The infection rate of MRMP in children has continued to rise after COVID-19. Doxycycline provides a reliable intervention option for clinical use. Clinical application needs to enhance the ability to identify and diagnose MRMP in children at an early stage and continuously monitor possible long-term adverse drug reactions.

  • Article
  • Yun ZHANG , Zhen FENG , Huiling LI , Tao WANG
    doi: 10.13683/j.wph.2025.09.014
    Objective

    To comprehensively evaluate the efficacy, safety and economy of romosozumab in the treatment of osteoporosis(OP) based on rapid health technology assessment(rHTA), to provide a reference for clinical decision-making.

    Methods

    PubMed, Embase, Cochrane Liarbry, Wanfang, China National Knowledge Infrastructure, VIP database and rHTA-related websites were retrieved. Literature was independently screened according to the inclusion and exclusion criteria respectively, data extraction and quality evaluation were conducted, and descriptive analysis was performed.

    Results

    A total of 19 articles were included, including 14 systematic reviews or meta-analyses, 3 pharmacoeconomic studies, and 2 rHTA reports. In terms of effectiveness, romosozumab can reduce the risk of fractures in patients with OP, especially vertebral fractures. It can increase bone density, reduce the risk of falls, and improve trabecular bone analysis parameters(P<0.05). In terms of safety, there was no statistically significant difference in the occurrence of adverse events such as drug withdrawal due to adverse reactions, serious adverse reactions, cardiovascular risks, cancer and osteoarthritis in OP patients after treatment with romosozumab(P>0.05), but it did increase the reactions at the injection site. In terms of economy, romosozumab followed by alendronate sodium had a more cost-effectiveness advantage than alendronate sodium alone.

    Conclusion

    Romosozumab has good efficacy and safety in the treatment of OP and can be regarded as a medium and long-term treatment option.

  • Article
  • Yanyan WANG , Miao WEI , Chunxia ZHANG , Jiaxiang ZHAO , Chao YAN , Yuan HE
    doi: 10.13683/j.wph.2025.09.015
    Objective

    To explore the influence of early warning boundary value, response and hospital operation practice in practices for pediatric hand, foot and mouth disease(HFMD) based on control map method in the era of intelligent medicine.

    Methods

    The baseline database of children with hand, foot and mouth disease collected by the Municipal Center for Disease Control and Prevention from February 2023 to February 2024 was selected, and two prediction models were established based on the control map method, swinging the baseline data for 1 and 2 weeks, and recorded as models A and B, and the early warning boundary values of the two models were compared.

    Results

    From February 2023 to February 2024, a total of 12 719 cases of hand, foot and mouth disease were reported. Using the"epidemic" criterion to assess the prevalence and sporadic cases during this period, model A identified weeks 28—34 as the epidemic phase (6 weeks), while model B identified weeks 30—34 as the epidemic phase(4 weeks). Screening test calculations determined that model A's preferred warning threshold was P95, which is higher than model B's preferred threshold P9.

    Conclusion

    Model A and model B were constructed and evaluated based on the mobile average method. Model A was determined as the preferred model, and its P95 warning threshold could more accurately distinguish the prevalence and distribution of HFMD.

  • Review
  • Junyi WANG , Haodong CHEN , Jiawei TANG , Songbai YANG , Shaoxin CHEN
    doi: 10.13683/j.wph.2025.09.016

    With the increase of invasive fungal infections, the use of antifungal drug has become more frequently, and the emergence of fungal resistance has become an inevitable problem. Given the limited availability of existing antifungal drugs and their severe side effects, the United States Food and Drug Administration has approved a new antifungal drug, ibrexafungerp, which is a semi-synthetic chemical derivative of the natural product enfumafungin. It has broad-spectrum antibacterial activity, demonstrates strong antibacterial activity against Candida and Aspergillus, including those echinocandins- and azoles-resistant strains. It's currently used in the clinical treatment of vulvovaginal candidiasis. Ibrexafungerp has good oral bioavailability and tolerance, with few adverse reactions. It is a β-1, 3-glucan synthase inhibitor with a new structure and has a good prospect in the clinical treatment of invasive fungal infections. This article reviewed the research and development process, clinical research and drug interactions of ibrexafungerp.

  • Review
  • Li'na CHEN , Hongling MA , Keran WANG , Lixin ZHANG , Guleng Siri
    doi: 10.13683/j.wph.2025.09.017

    Non-alcoholic fatty liver disease(NAFLD) has become one of the most prevalent chronic liver diseases worldwide, with its incidence rising rapidly alongside the increasing prevalence of obesity and metabolic syndrome. At present, the treatment of NAFLD mainly relies on lifestyle intervention, but there is a lack of specific drugs. With in-depth research into the pathophysiological mechanisms of NAFLD, multiple drugs target metabolic disorders, inflammation, and fibrosis have become a hot topic. This article reviewed the latest advancements in NAFLD drug development, statistically analyzed global research trends and therapeutic hotspots, focused on introducing the clinical trial outcomes of metabolic modulators, anti-inflammatory or anti-fibrotic agents, and emerging targets, and discussed the future directions in this field.

  • Pharmacy administration
  • Qian XING , Hui SUN , Wendi CHENG , Xiaochen PENG , Haiyin WANG
    doi: 10.13683/j.wph.2025.09.018

    Since the implementation of pharmaceutical price disclosure in 2007, Australia has gradually implemented a mechanism for periodic adjustment of pharmaceutical prices, which has achieved remarkable results in controlling pharmaceutical prices, reducing healthcare expenditures, and ensuring that prices are open and reasonable. This paper analysed the background, adjustment mechanism and implementation process of the statutory price reduction and exemption system for PBS medicines, as well as the overall implementation effect. Finally, based on the practical experience of Australia, which provided a reference for optimizing the classification renewal rules of medical insurance drugs and building a long-term price management in China.

  • Pharmacy administration
  • AIZEZIJIANG Aierken , Hongbin YI , Ningning WANG , Jiangtao ZHANG , HAISHAERJIANG Wushouer , Xiaodong GUAN , Luwen SHI , KAISAIER Abudukeremu
    doi: 10.13683/j.wph.2025.09.019
    Objective

    To evaluate the impact of the pilot policy on the medical insurance payment standard for pilot drugs of a grade-A tertiary hospital in Xinjiang, and to provide empirical reference for the further optimization of medical insurance payment standard policies in Xinjiang.

    Methods

    Extracted the monthly data of pilot drug prices, usage amounts and usage quantities from the target hospital medicine management information system, checked the data integrity, and use the intermittent time series model to analyze the pilot drugs with high data integrity.

    Results

    A total of 5 pilot drugs were included. After the implementation of the pilot policy of medical insurance payment standard, the prices of Jinshuibao tablets, enteral nutrition emulsion and iron sucrose injection in the target hospitals showed a significant downward trend(P<0.05). The usage volume and expenditrue of Jinshuibao tablets immediately increased, while silymarin capsules and magnesium isoglycyrrhizinate injection showed a downward trend(P<0.05).

    Conclusion

    The prices and costs of most of the pilot drugs in the target hospitals have decreased significantly, and the usage amounts have also reduced, which helps to alleviate the financial burden of patients and save the medical insurance fund. Changes in the use of the pilot drugs vary and require further analysis in conjunction with other information. In addition, the pilot policy of medical insurance payment standard in Xinjiang still has a large lag.

News